Viridian Therapeutics, Inc. (VRDN)
Develops antibody treatments for thyroid eye disease and other rare immune disorders
$19.39-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+11.4%
The outlook
VRDN trades near $19.39, sitting in the lower quarter of its 52-week range. Analyst consensus is strongly bullish with an average price target roughly 86% above the current level. Price momentum versus moving averages shows mixed signals, though the overall lean reflects solid analyst support.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 16 analysts
Price trendMixed vs its moving averages
52-week range29% of the way from its 52-week low to high
Price targetAvg target +86% vs current price
Analyst price target
~12-month · 16 analysts$36.13average target+86.3% vs now
Now $19.39
Low $22.00High $50.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.14B
52-wk high
$34.29
52-wk low
$13.18
50-day avg
$17.76
200-day avg
$24.02
Trailing P/E
—